---
layout: default
title: Activated Charcoal Aloe Carbo Animalis Hamamelis V
parent: 僅模型預測 (L5)
nav_order: 166
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Aloe Carbo Animalis Hamamelis V
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Preparation: TxGNN Evaluation Incomplete — Insufficient Data

## One-Sentence Summary

This entry contains a 15-component complex preparation including homeopathic substances (Lachesis Muta Venom, Nux-Vomica, Sepia Officinalis, Sulfur, Lycopodium) alongside botanical astringents and venotropic agents historically associated with anorectal conditions. The TxGNN model could not generate a repurposing prediction because no DrugBank ID was matched and no predicted indications were returned. As a result, **no evidence table, clinical trial data, or repurposing score is available** for this candidate.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no regulatory record in Taiwan or US) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — but no prediction was generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This candidate is a **15-ingredient combination** whose components span four distinct pharmacological categories:

1. **Activated adsorbents** — Activated Charcoal, Carbo Animalis
2. **Botanical venotropics / astringents** — Hamamelis Virginiana, Horse Chestnut, Krameria Lappacea, Paeonia Officinalis, Aloe
3. **Classical homeopathic dilutions** — Lachesis Muta Venom, Lycopodium Clavatum Spore, Sepia Officinalis Juice, Strychnos Nux-Vomica Seed, Sulfur, Nitric Acid, Hydrochloric Acid
4. **Mineral supplement** — Tribasic Calcium

The ingredient profile (particularly Hamamelis, Horse Chestnut, Krameria, Paeonia, Nux-Vomica, Nitric Acid, and Sepia) is consistent with multi-component **anorectal / hemorrhoid** preparations common in European homeopathic markets. However, TxGNN operates on single-entity DrugBank nodes; this multi-ingredient entry has no `drugbank_id`, so the knowledge graph cannot assign a node identity and no graph traversal prediction is possible.

Mechanistic analysis is therefore not feasible at this stage.

---

## Safety Considerations

Please refer to each individual component's package insert and regulatory monograph for safety information. Notable concerns at the ingredient level include:

- **Strychnos Nux-Vomica Seed** — contains strychnine alkaloids; narrow therapeutic index in non-homeopathic doses
- **Lachesis Muta Venom** — snake-derived; hemotoxic at pharmacological concentrations
- **Nitric Acid / Hydrochloric Acid** — corrosive agents requiring strict dilution verification

No formal DDI data was retrieved for this combination formulation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline cannot evaluate a multi-ingredient entry without a resolved DrugBank node. Additionally, this preparation contains homeopathic components whose efficacy is not recognised by regulatory bodies in conventional evidence frameworks, making repurposing analysis methodologically inappropriate without decomposition into individual active ingredients.

**To proceed, the following is needed:**

- **Ingredient decomposition**: Evaluate each pharmacologically active component (Hamamelis, Horse Chestnut, Krameria, Activated Charcoal) as a separate TxGNN candidate with its own DrugBank ID
- **Exclude homeopathic dilutions**: Components used at homeopathic potencies (e.g., Lachesis, Sepia, Sulfur, Lycopodium, Nux-Vomica) should be flagged as out-of-scope for TxGNN, which requires conventional pharmacological concentrations
- **Confirm product identity**: Verify whether this formulation corresponds to a known branded product (e.g., a rectal suppository or cream marketed in Europe) to locate any existing regulatory record
- **Safety document retrieval**: Obtain the originating manufacturer's SmPC or product insert to establish contraindications and warnings before any clinical assessment
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

